Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.

Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.

The anti-CD49d monoclonal antibody natalizumab is currently an effective therapy against the relapsing-remitting form of multiple sclerosis (RRMS). Natalizumab therapeutic efficacy is limited by the reactivation of the John Cunningham polyomavirus (JCV) and development of progressive multifocal leuk...

Full description

Bibliographic Details
Main Authors: Marco Iannetta, Maria Antonella Zingaropoli, Anna Bellizzi, Manuela Morreale, Simona Pontecorvo, Alessandra D'Abramo, Alessandra Oliva, Elena Anzivino, Sara Lo Menzo, Claudia D'Agostino, Claudio Maria Mastroianni, Enrico Millefiorini, Valeria Pietropaolo, Ada Francia, Vincenzo Vullo, Maria Rosa Ciardi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4972347?pdf=render

Internet

http://europepmc.org/articles/PMC4972347?pdf=render

Similar Items